Requirement for Ras/Raf/ERK pathway in naringin-induced G₁-cell-cycle arrest via p21WAF1 expression

Dong-Ill Kim¹, Se-Jung Lee¹, Sook-Bok Lee¹, Keerang Park², Won-Jae Kim³ and Sung-Kwon Moon*¹

Department of Food and Biotechnology, Chungju National University, Chungju, Chungbuk 380-702, South Korea, ¹Department of Food and Nutrition, Brain Korea 21 Project, Yonsei University, Seoul 120-794, Korea, ²Department of Biotechnology, Juseong College, Chungbuk 363-794, Korea, and ³Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 361-763, South Korea

¹To whom correspondence should be addressed. Tel: +82 43 841 5520; Fax: +82 43 841 5240; Email: sumoon66@dreamwiz.com

Naringin, an active flavonoid found in citrus fruit extracts, has pharmacological utility. The present study identified a novel mechanism of the anticancer effects of naringin in urinary bladder cancer cells. Naringin treatment resulted in significant dose-dependent growth inhibition together with G₁-phase cell-cycle arrest at a dose of 100 μM (the half-maximal inhibitory concentration) in 5637 cells. In addition, naringin treatment strongly induced p21WAF1 expression, independent of the p53 pathway, and down-regulated expression of cyclins and cyclin dependent kinases (CDKs). Moreover, treatment with naringin induced phosphorylation of extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase and c-Jun N-terminal kinase. Among the pathways examined, only PD98059, an ERK-specific inhibitor, blocked naringin-dependent p21WAF1 expression. Consistently, blockade of ERK function reversed naringin-mediated inhibition of cell proliferation and decreased cell-cycle proteins. Furthermore, naringin treatment increased both Ras and Raf activation. Transfection of cells with dominant-negative Ras (RasN17) and Raf (RafS621A) mutant genes suppressed naringin-induced ERK activity and p21WAF1 expression. Finally, the naringin-induced reduction in cell proliferation and cell-cycle proteins also was abolished in the presence of RasN17 and RafS621A mutant genes. These data demonstrate that the Ras/Raf/ERK pathway participates in p21WAF1 induction, subsequently leading to a decrease in the levels of cyclin D1/CDK4 and cyclin E–CDK2 complexes and naringin-dependent inhibition of cell growth. Overall, these unexpected findings concerning the molecular mechanisms of naringin in 5637 cancer cells provide a theoretical basis for the therapeutic use of flavonoids to treat malignancies.

Introduction

Bladder cancer is the fifth most common cancer in men and eighth most common in women. Bladder cancer has a very high incidence of recurrence—at 70% or greater (1). Bladder cancer comprises a wide range of tumors, including transitional cell carcinoma (2,3). Transitional cell carcinoma is classified histopathologically into three types: superficial tumors (papillary tumors), tumors confined to the bladder wall (pTa and pT1 tumors) and invasive tumors (stages T2–T4). Patients with superficial bladder cancer are at risk for recurrence of the disease and/or progression to invasive diseases, which is potentially lethal (4). For these people, effective preventive measures are needed.

The p21WAF1 is the primary known mediator of checkpoint-induced arrest during the G₁ phase of the cell cycle. The p21WAF1 is a target for diverse signals, which cause cell growth arrest and promote differentiation. Introduction of p21WAF1 protein into human transformed and malignant cells induces cell-cycle arrest (5–7). The kinase activities of the cyclin–cyclin dependent kinase (CDK) complexes are negatively regulated by CDK inhibitors, such as p21WAF1 (8,9), which blocks cell-cycle progression by binding and inactivating the cyclin–CDK complex system (6,7). A mutation in p21WAF1 that specifically abrogated binding to CDKs was identified in cells isolated from a primary breast tumor (10), suggesting that p21WAF1 has tumor-suppressive activity.

The mitogen-activated protein kinase (MAPK) family of enzymes is composed of related serine/threonine protein kinases that integrate diverse signals, thereby directing cellular responses to proliferative cues or stressful stimuli (11–13). Three major mammalian MAPK subfamilies have been described: extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs, also called stress-activated protein kinase) and p38 MAPKs. In general, JNK and p38 MAPKs are only weakly activated by growth factors, but are highly activated in response to a variety of stress signals, including tumor necrosis factor, ionizing and short-wavelength ultraviolet irradiation (UVC) and hyperosmotic stress. Activation of JNK and p38 MAPK is most frequently associated with induction of apoptosis (14,15). In contrast, ERK activation is typically associated with cell survival, proliferation and differentiation in response to activation by mitogens and cell survival factors (15–17). However, activation of ERKs has recently been found to contribute to cell death in neuronal cells, human medullary thyroid cancer cells and keratinocytes in vitro (18–20). Overactivity of the ERK-mediated pathway promotes oncogenesis in a variety of cell types (21,22). Furthermore, the ERK pathway has been implicated in p21WAF1 upregulation and in cell-cycle arrest mediated by pharmacological agents in colon cancer cells (23).

Flavonoids are naturally occurring polyphenols that are present in a wide variety of fruits and vegetables. Naringin (the glycoside of the flavonone, naringenin), a bioflavonoid found in grapefruit and other citrus fruits, has antioxidant (24) and antiatherogenic effects (8). Naringin also has proven to have antiviral activity (9) and to reduce the level of cytotoxicity P450 1A2 protein (25). Moreover, recent studies have shown that increased dietary consumption of naringin is associated with reduced risk of certain cancers, such as breast and lung cancers (26,27). Although many studies have analyzed the effects of naringin on tumor growth inhibition in several cell lines (26–28), the relevant pathway integrating cell-cycle regulation and signaling pathways involved in growth inhibition in cancer cells remains to be identified.

The present study sought to examine the roles of the MAPK-signaling pathways in regulating naringin-induced inhibition of cell growth in 5637 bladder cancer cells. Although ERK, JNK and p38 MAPK all were activated in response to naringin treatment, only ERK activity appeared to be involved in regulating cell growth. Using a variety of strategies to manipulate ERK activity, the Ras/Raf/ERK pathway was identified as a novel mechanism of naringin-induced cell growth inhibition that was mediated via p21WAF1-induced cell-cycle arrest.

Materials and methods

Materials

Naringin was purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan). Polyclonal antibodies to cyclin E, CDK2 and CDK4 were obtained from Santa Cruz (Santa Cruz Biotechnology, CA). Polyclonal antibodies to cyclin D1, p21WAF1, p53, p27, ERK, Raf, phospho-Raf, phospho-ERK, p38 MAPK, phospho-p38 MAPK, JNK and phospho-JNK were obtained from New England Biolabs (Ipswich, MA). PD98059, SP600125 and SB203580 were obtained from Calbiochem (San Diego, CA). Anti-Ras antibody was obtained...
Naringin reduces the proliferation of human urinary bladder cancer cells

To investigate the inhibitory effect of naringin on proliferation of bladder cancer cells, 5637 cells were grown in medium containing 10% fetal bovine serum in the absence or presence of various concentrations of naringin (0–150 μM) for 24 h. The results of the MTT assay (Figure 1A) demonstrated that naringin significantly inhibited cell viability in a concentration-dependent manner. In addition, the effect of naringin on cell proliferation was determined by [3H]thymidine incorporation after treatment with various concentrations of naringin for 24 h. Naringin had a concentration-dependent inhibitory effect on 5637 cell growth (Figure 1B). Vehicle (ethanol) had no effect on the basal levels of cell viability and thymidine incorporation (data not shown).

Naringin-induced G1-phase cell-cycle arrest

Flow cytometric analysis was performed to determine whether naringin-induced cell growth inhibition was due to cell-cycle arrest at a specific point in the cell cycle. Upon treatment with 100 μM naringin (the half maximal inhibitory concentration as assessed by MTT assay and [3H]thymidine incorporation into cells), a flow cytometric analysis demonstrated that naringin treatment (100 μM) resulted in accumulation of significant numbers of cells in the G1 phase of the cell cycle, indicative of cell-cycle arrest (Figure 2C–G). Next, the effect of naringin on cell-cycle regulatory molecules, operative in the G1 phase of the cell cycle, was examined. To determine if naringin-induced growth inhibition of 5637 cells was due to decreased activation of the cell-cycle machinery, expression of cell-cycle regulatory molecules was examined using immunoblot and kinase assays. Treatment of cells with naringin for 24 h resulted in a dose-dependent decrease in the expression of cyclin D1 and cyclin E, as well as CDK2 and CDK4 (Figure 2A). The kinase activities associated with the CDKs drive cell-cycle progression through the transition checkpoints because they activate cyclins—the essential components of cyclin–CDK complexes. Therefore, kinase activities associated with CDK2 and CDK4 were assessed in naringin-treated cells. CDK complexes were immunoprecipitated using specific anti-CDKs antibodies, and the levels of CDK-associated kinase activities were measured using retinoblastoma (Rb) protein or histone H1 as the substrate. The kinase activities of the CDK2 and CDK4 immunoprecipitates were markedly inhibited after treating 5637 cells with naringin (Figure 2B).

Naringin-induced cell-cycle arrest is associated with upregulation of p21WAF1

The effect of naringin on the induction of p21WAF1, which regulates progression of the cell cycle at the G1–S-phase transition checkpoint, was examined using immunoblotting (6,7). Immunoblot analysis revealed that treatment of 5637 cells with naringin resulted in significant dose-dependent induction of p21WAF1 compared with untreated cells (Figure 2C). However, naringin had no effect on induction of p27. Moreover, under similar experimental conditions, expression of the p53 tumor suppressor protein was unaffected, suggesting that it is unlikely that p27 and p53 are involved in the cell-cycle arrest induced by naringin (Figure 2C).

Naringin treatment strongly induced p21WAF1 expression in 5637 cells. Because induction of p21WAF1 has been shown to increase interaction between p21WAF1 and CDKs, leading to a decrease in kinase activity (6,7), the effects of naringin on interactions between p21WAF1 and CDKs were examined. To assess the effect of naringin on this protein–protein interaction, cell extracts were subjected to immunoprecipitation using anti-CDK2 or –CDK4 antibodies. After

Results

Naringin reduces the proliferation of human urinary bladder cancer cells

To investigate the inhibitory effect of naringin on proliferation of bladder cancer cells, 5637 cells were grown in medium containing 10% fetal bovine serum in the absence or presence of various concentrations of naringin (0–150 μM) for 24 h. The results of the MTT assay (Figure 1A) demonstrated that naringin significantly inhibited cell viability in a concentration-dependent manner. In addition, the effect of naringin on cell proliferation was determined by [3H]thymidine incorporation after treatment with various concentrations of naringin for 24 h. Naringin had a concentration-dependent inhibitory effect on 5637 cell growth (Figure 1B). Vehicle (ethanol) had no effect on the basal levels of cell viability and thymidine incorporation (data not shown).

Naringin-induced G1-phase cell-cycle arrest

Flow cytometric analysis was performed to determine whether naringin-induced cell growth inhibition was due to cell-cycle arrest at a specific point in the cell cycle. Upon treatment with 100 μM naringin (the half maximal inhibitory concentration as assessed by MTT assay and [3H]thymidine incorporation into cells), a flow cytometric analysis demonstrated that naringin treatment (100 μM) resulted in accumulation of significant numbers of cells in the G1 phase of the cell cycle, indicative of cell-cycle arrest (Figure 2C–G). Next, the effect of naringin on cell-cycle regulatory molecules, operative in the G1 phase of the cell cycle, was examined. To determine if naringin-induced growth inhibition of 5637 cells was due to decreased activation of the cell-cycle machinery, expression of cell-cycle regulatory molecules was examined using immunoblot and kinase assays. Treatment of cells with naringin for 24 h resulted in a dose-dependent decrease in the expression of cyclin D1 and cyclin E, as well as CDK2 and CDK4 (Figure 2A). The kinase activities associated with the CDKs drive cell-cycle progression through the transition checkpoints because they activate cyclins—the essential components of cyclin–CDK complexes. Therefore, kinase activities associated with CDK2 and CDK4 were assessed in naringin-treated cells. CDK complexes were immunoprecipitated using specific anti-CDKs antibodies, and the levels of CDK-associated kinase activities were measured using retinoblastoma (Rb) protein or histone H1 as the substrate. The kinase activities of the CDK2 and CDK4 immunoprecipitates were markedly inhibited after treating 5637 cells with naringin (Figure 2B).

Naringin-induced cell-cycle arrest is associated with upregulation of p21WAF1

The effect of naringin on the induction of p21WAF1, which regulates progression of the cell cycle at the G1–S-phase transition checkpoint, was examined using immunoblotting (6,7). Immunoblot analysis revealed that treatment of 5637 cells with naringin resulted in significant dose-dependent induction of p21WAF1 compared with untreated cells (Figure 2C). However, naringin had no effect on induction of p27. Moreover, under similar experimental conditions, expression of the p53 tumor suppressor protein was unaffected, suggesting that it is unlikely that p27 and p53 are involved in the cell-cycle arrest induced by naringin (Figure 2C).

Naringin treatment strongly induced p21WAF1 expression in 5637 cells. Because induction of p21WAF1 has been shown to increase interaction between p21WAF1 and CDKs, leading to a decrease in kinase activity (6,7), the effects of naringin on interactions between p21WAF1 and CDKs were examined. To assess the effect of naringin on this protein–protein interaction, cell extracts were subjected to immunoprecipitation using anti-CDK2 or –CDK4 antibodies. After
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and blotting, membranes were probed with anti-p21WAF1. In naringin-treated cells, the association of CDK2 with p21WAF1 was maintained at high levels (Figure 2D). Levels of p21WAF1–CDK4 complexes also were increased in 5637 cells 24 h after naringin treatment (Figure 2D). These results suggest that the increased interaction between induced p21WAF1 and CDKs plays an important regulatory role in inhibiting CDK kinase activity, leading to G1 arrest after naringin treatment in human bladder 5637 cancer cells. Moreover, p21WAF1 promoter activity was increased as a result of naringin treatment (Figure 2E). Collectively, these results demonstrate that naringin induces expression of p21WAF1 protein and enhances p21WAF1 promoter activity.

Ras/Raf/ERK activation in naringin-induced growth inhibition

Next, we examined the effect of naringin on cell viability and growth inhibition using another bladder cancer cell line T24 and normal fibroblast cells. As shown in Figure 3C and D, treatment with naringin (50–150 μM) had no effect on cell growth in culture of normal fibroblast cells. However, under similar experimental conditions, naringin significantly inhibited the cell viability and cell proliferation in T24 cells (Figure 3C and D). In addition, naringin treatment strongly induced p21WAF1 expression and phosphorylation of ERK (Figure 3E–G). These results suggest that naringin has a general inhibitory effect in bladder cancer cells.

Naringin-induced p21WAF1 is blocked by PD98059, a specific inhibitor of ERK

Because MAPK activity was induced by naringin, the role of p21WAF1 induction in MAPK activity was investigated. To elucidate
the signal cascade triggered by MAPK, the dependence of p21WAF1 induction on the MAPK-signaling pathway was investigated. Thus, 5637 cells were pretreated for 40 min with or without kinase inhibitors, such as PD98059, SB203580 and SP600125, followed by exposure to 100 μM naringin. As shown in Figure 4A, the naringin-induced increase in p21WAF1 expression was reduced to the level of the control by PD98059 treatment. SP600125 had a slight reversed effect on naringin-mediated p21WAF1 expression. However, SB203580 had no apparent effect on naringin-induced p21WAF1 levels. In addition, CDK2 and CDK4 protein levels also were reversed after PD98059 treatment for 24 h (Figure 4B). These results strongly suggest that the ERK-signaling pathway is required for the regulation of p21WAF1-mediated G1-phase cell-cycle arrest in response to naringin.

Effects of a dominant-negative RasN17 mutant gene on naringin-mediated ERK, p21WAF1, growth inhibition and decreased CDKs levels

The results described above led to an examination of whether or not Ras, an activator of the ERK1/2-signaling pathway, is involved in naringin-induced growth inhibition. First, the ability of naringin to induce activation of Ras in 5637 cells was examined. To achieve this objective, cellular levels of the active form of Ras (Ras-GTP) were analyzed via specific binding to GST-conjugated c-Raf immobilized on agarose. The bound Ras-GTP was then assayed by immunoblotting with an anti-Ras antibody. As shown in Figure 5A, naringin is capable of inducing activation of Ras in 5637 cells, whereas the expression of Ras remained unchanged after treatment with naringin.

To elucidate whether Ras activation is required for naringin-induced ERK phosphorylation, 5637 cells were transfected with a dominant-negative Ras (RasN17) or an empty vector (EV) and then treated with naringin. As shown in Figure 5B, naringin treatment of 5637 cells, or of cells transfected with the EV, induced ERK1/2 activity. Transfection with RasN17 resulted in near complete suppression of ERK1/2 activity, suggesting that naringin may activate ERK through a Ras-dependent pathway in 5637 cells.

The involvement of Ras in p21WAF1 expression and naringin-induced inhibition of cell growth was further investigated by transfecting a dominant-negative RasN17 mutant gene into 5637 cells. As shown in Figure 5C, D and E, naringin treatment of 5637 cells, or of cells transfected with the EV, induced p21WAF1 expression and decreased [3H]thymidine incorporation and CDK2 and CDK4 expression. Transfection with the RasN17 gene blocked naringin-induced
p21WAF1 expression and prevented the naringin-induced decrease in [\(^3\)H]thymidine incorporation and in CDK2 and CDK4 expression. These results show that naringin regulates p21WAF1 expression, growth inhibition and decreases CDKs in 5637 cells by activating a Ras-dependent pathway. Collectively, these results suggest that the Ras/ERK-signaling pathway must be involved in p21WAF1-mediated G1-phase cell-cycle arrest and growth inhibition in 5637 cells in response to naringin treatment.
and among these naturally occurring compounds, naringin has been
industrial communities. Citrus fruits contain various flavonoids,
ment of antitumor agents has become a critical topic in the scientific
Recently, the use of naturally occurring compounds in the develop-
Discussion
5637 cells.
function of antitumor agents has become a critical topic in the scientific
5637 cells. The 5637 cells were transiently transfected with an EV or with RasN17. Cellular content of phosphorylated ERK1/2, p21WAF1, CDK2 and CDK4 was analyzed by immunoblotting as described in the Materials and Methods section. (D) Thymidine uptake experiments were determined as described under Materials and Methods. Results are presented as means ± SEs from three triplicate experiments. **P < 0.01 compared with no naringin treatment in 5637 cells transfected with the RasN17 mutant gene.

The RafS621A mutant gene reversed the effects of naringin treatment on growth inhibition, CDKs levels, ERK activation and p21WAF1

Fig. 5. Effects of a dominant-negative RasN17 mutant gene in the naringin-mediated cell growth inhibition (A) Time course for naringin-induced Ras activation. The 5637 cells were stimulated by naringin for 6 or 12 h and lysed. Cellular content of Ras active form (Ras-GTP) was analyzed by immunoblotting as described in Materials and Methods. (B, C and E) Immunoblot of ERK1/2, p21WAF1, CDK2 and CDK4 in cells after 12 h treatment with naringin. Cells were transfected with an EV or with RasN17. Cellular content of phosphorylated ERK1/2, p21WAF1, CDK2 and CDK4 was analyzed by immunoblotting as described in the Materials and Methods section. The importance of MAPK-signaling pathways in regulating inhibition of cell growth during conditions of stress has been widely in-

However, the exact molecular mechanisms underlying the cellular effects resulting from naringin treatment have yet to be fully ex-

Treatment of 5637 cells with naringin (50–150 μM) resulted in decreased cell viability and thymidine uptake, but not in normal fi-

The RafS621A mutant gene reversed the effects of naringin treatment on growth inhibition, CDKs levels, ERK activation and p21WAF1

The requirement for the activation of the Ras, Raf and ERK pathways, which are associated with cell proliferation, has been demonstrated for various cell functions in response to various stimuli (37–39). The activation of Raf, which is a downstream molecule of Ras, also was observed in naringin-treated 5637 cells. Figure 6A shows an immu-

Discussion
Recently, the use of naturally occurring compounds in the development of antitumor agents has become a critical topic in the scientific and industrial communities. Citrus fruits contain various flavonoids, and among these naturally occurring compounds, naringin has been pharmacologically evaluated as a potential anticancer agent (26–28). However, the exact molecular mechanisms underlying the cellular effects resulting from naringin treatment have yet to be fully ex-

The importance of MAPK-signaling pathways in regulating inhibited cell growth during conditions of stress has been widely in-

1706
MAPK-signaling pathway and the regulation of p21WAF1, pharmacological inhibitors (PD98059, SB203580 and SP600125) were employed. Of considerable interest in this study was the marked decrease in naringin-induced expression of p21WAF1 only by PD98059 treatment. Under the same experimental conditions, SB203580 and SP600125 treatment had no effect on naringin-induced p21WAF1 expression (Figure 4A). These results suggest that activation of these two kinases is not required for naringin-induced p21WAF1 expression, although naringin activates both p38 kinase and JNK2. The ERK-signaling pathway appears to involve multiple signal transduction pathways, which are used to accomplish a variety of functions (18–20,23). Many studies have supported the general view that activation of the ERK pathway delivers a survival signal that counteracts the proapoptotic effects of JNK and p38 MAPK activation (11–15). However, recent reports have maintained that sustained activation of ERK also is involved in apoptosis (18–20). Robust ERK stimulation has been reported to suppress cell-cycle progression, via induction of cell-cycle inhibitor proteins, including p21WAF1 and p27KIP (42). The results of the present study suggest that ERK signaling is involved in naringin-induced inhibition of cell growth due to induction of p21WAF1 in 5637 cells. This study identified the first example of an interaction between activation of the ERK-signaling pathway and regulation of p21WAF1 in cells treated with flavonoids.

The effects of naringin on cell proliferation and on the cell-cycle-associated proteins, CDK2 and CDK4, were confirmed by inhibition of ERK. Consistent with the observations that naringin treatment inhibited cell growth and modulated cell-cycle-associated proteins, blockade of ERK with PD98059 rescued cell proliferation and cell-cycle-associated proteins. These data provide evidence that ERK is a key mediator of naringin-induced inhibition of cell growth.

In general, the ERK cascade is activated by mitogenic stimuli and is believed to mediate both cell proliferation and survival (15–17). The activation of ERK by extracellular growth signals is mediated via activation of a small G-protein, Ras, or its downstream effector, Raf, which is the target molecule of activated Ras. Ultimately, ERK activation enhances cell proliferation (37–39,43,44). In contrast, sustained expression of activated Ras or Raf can elicit cell growth arrest in many cell types in vitro (45,46). Ras/Raf-mediated growth arrest is accompanied by induction of CDK1, such as p16INK4a, p21WAF1, p27KIP1 and tumor suppressor p53, and by downregulation of phosphorylation of Rb or of the E2F family (20,45,46). However, the mechanism by which Ras or Raf activation, in response to flavonoid induction, promotes cell growth arrest remains to be elucidated. Accordingly, the involvement of a Ras/Raf-mediated pathway in naringin-induced inhibition of 5637 cell growth was examined because both Ras and Raf were activated by naringin. In this study, to determine whether Ras/Raf is required for naringin-induced activation of ERK, 5637 cells were transfected with dominant-negative Ras (RasN17) and dominant-negative Raf (RafS621A). Naringin-induced ERK activation was suppressed by transfection with the dominant-negative mutants of RasN17 and RafS621A in cells, suggesting that Ras/Raf plays a key role in naringin-induced activation of the ERK-signaling cascade in 5637 cells.

To gain further insight into the mechanism of naringin-mediated cell growth inhibition in 5637 cells, the influence of Ras/Raf activation on the ERK1/2 kinase cascades that control cell growth and cell-cycle machinery proteins was examined. Transfection of cells with RasN17 and RafS621A mutant genes abolished the naringin-induced inhibition of cell growth, together with upregulation of p21WAF1 levels and inhibition of CDK2 and CDK4 expression. The results obtained for the RasN17 and RafS621A overexpression experiments now provide evidence that the Ras/Raf-signaling pathway is involved in naringin-induced inhibition of cell growth via p21WAF1-mediated cell-cycle regulation in 5637 cells. Thus, a Ras/Raf-dependent ERK-signaling pathway may be responsible for naringin-induced inhibition of cell proliferation.

The present study provides important new insight into the molecular mechanisms of the effects of naringin in 5637 cancer cells. First,
naringin reduces cell viability and cell proliferation. In addition, naringin arrests the cell cycle at the G1 phase in 5637 cells and the naringin-induced cell-cycle arrest can be attributed to the inhibition of cyclin D1/CDK4 and cyclin E–CDK2 complexes by the increased expression of p21WAF1, independent of p53 protein levels. Finally, the naringin-induced inhibition of cell growth appears to be linked to the activation of Ras/Raf/ERK through p21WAF1-mediated G1-phase cell-cycle arrest. The findings of the present study may, in part, explain the therapeutic effects of naringin for treatment of urinary bladder cancer.

The results of the present study are a significant step forward in understanding the activity of flavonoids, and it also sheds new light on the molecular mechanisms underlying the unexpected effects of the flavonoid, naringin. Although recent data from our laboratory have demonstrated the importance of the ERK-signaling pathway in some natural products (unpublished data), additional studies are required to clearly elucidate the relationship between the ERK pathway and the activity of other flavonoids.

Others have found that suppression of the ERK pathway is important in flavonoid-induced inhibition of cell growth. Recent studies have suggested that flavonoid inhibition of ERK activation represents a primary approach for treatment of human malignancies. Although this may indeed be true, the results of the present study indicate that this approach should not be generalized to all types of cancer. In contrast, the findings of the present study, which support a role for the Ras/Raf/ERK-signaling pathway in enhancing naringin-induced cell growth inhibition, suggest that strategies designed to activate this signal cascade may enhance the therapeutic effectiveness of the flavonoid, naringin.

Funding

Regional Industrial Technology Development Program (10018327) from the Ministry of Commerce, Industry and Energy in Korea.

Acknowledgements

Conflict of Interest Statement: None declared.

References


Received October 9, 2007; revised February 5, 2008; accepted February 16, 2008